Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.66, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $104.26 |
52-Week Low | $11.58 | $79.58 |
Market Cap | — | $17.97B |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.82, down 1.23% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF generates consistent weekly dividends but faces structural limitations in capturing Nvidia's full upside potential. Recent analyst downgrades highlight concerns about declining volatility reducing option income effectiveness and potential NAV erosion despite the attractive 39.7% annualized distribution rate.
The outlook remains cautious as NVDY's strategy sacrifices long-term capital appreciation for income generation. While weekly distributions provide cash flow, the fund's structural cap on upside participation and reliance on Nvidia's volatility create headwinds. Investors seeking pure Nvidia exposure may find better alternatives, while income-focused investors should weigh the high distribution rate against potential principal erosion.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
